通过建立最优暴露-毒性阈值减少洛拉替尼相关不良事件
研究基于发现队列(n=46)和外部验证队列(n=52)探索洛拉替尼血药暴露与严重毒性的关系。合并队列(n=98)分析显示暴露越高毒性风险越高(校正后sHR 3.45,95%CI 1.54-7.72,p=0.003),发现队列确定最优阈值147 ng/mL(AUC 0.81),低于阈值者毒性风险更低。
要点
- 洛拉替尼暴露越高,严重毒性风险越高。
- Ctrough阈值147 ng/mL可区分毒性风险高低。
- 高于阈值者早期减量或可预防严重毒性。
核心结论
- 洛拉替尼血浆暴露与严重毒性风险显著相关,暴露越高风险越大。
- Ctrough高于147 ng/mL的患者早期减量可能预防严重毒性并改善耐受性。
研究设计与样本
- 研究采用发现队列(n=46)和外部验证队列(n=52),合并队列n=98。
- 严重毒性定义为不良事件≥3级或导致剂量中断、减量、停药或患者住院。
主要发现
- 发现队列和验证队列中严重毒性发生率分别为43%和46%,以神经认知症状、代谢紊乱和水肿为主。
- 合并队列竞争风险分析中,对数转换Ctrough校正后亚分布风险比为3.45(95%CI 1.54-7.72,p=0.003),校正年龄和体能状态。
- 发现队列ROC分析确定最优阈值147 ng/mL,曲线下面积0.81。
- 低于阈值者在发现队列和验证队列中毒性风险更低,亚分布风险比分别为0.26和0.35(p=0.003和0.012)。
关键数值与推荐
- Ctrough最优毒性阈值为147 ng/mL(发现队列ROC分析,AUC 0.81)。
- Ctrough高于阈值者约占总患者的三分之一。
临床怎么用
- 对洛拉替尼Ctrough高于147 ng/mL的患者,可考虑早期减量以预防严重毒性。
- 暴露-guided剂量调整可能改善治疗耐受性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lorlatinib is highly effective in patients with ALK-positive NSCLC but frequently causes toxicity, which requires dose modifications or treatment cessation. To explore exposure-guided dosing, we assessed the relationship between lorlatinib plasma exposure and severe toxicities using data from two cohorts of patients: a discovery cohort and an external validation cohort (n = 46 and n = 52, respectively). Severe toxicity, defined as adverse events grade more than or equal to 3 or those leading to dose interruption, reduction, or cessation or patient hospitalization, was observed in 43% and 46% of patients, predominantly neurocognitive symptoms, metabolism disorders, and edema. In a competing risk analysis, higher lorlatinib exposure significantly increased the risk of toxicity (log-transformed Ctrough adjusted subdistribution hazard ratio: 3.45 [95% confidence interval: 1.54-7.72; p = 0.003]) in the combined cohorts (n = 98), corrected for age and performance status. An optimal threshold of 147 ng/mL was identified in the discovery cohort using receiver operating characteristic analysis (area under the curve: 0.81). Patients below this threshold had a lower risk of toxicity in both the discovery cohort and the validation cohort (subdistribution hazard ratio: 0.26 and 0.35; p = 0.003 and 0.012, respectively). On the basis of results from these two independent cohorts of patients, early dose reduction in patients with a lorlatinib Ctrough above the toxicity threshold, representing approximately one-third of patients, might prevent severe toxicity and improve treatment tolerability.
引用
- Lanser DAC, van Merendonk LN, Veerman GDM, et al. Brief Report: Reducing Lorlatinib-Related Adverse Events by Establishing the Optimal Exposure-Toxicity Threshold in Patients With NSCLC. J Thorac Oncol. 2026. PMID: 42462816. doi:10.1016/j.jtho.2026.104093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。